Natural products as leads to potential drugs: An old process or the new hope for drug discovery?

Journal of Medicinal Chemistry

Volumn 51, Issue 9, 2008, Pages 2589-2599

  Newman, David J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A 23573; ADENINE DERIVATIVE; ANTINEOPLASTIC AGENT; ASTEMIZOLE; BENZOPYRAN DERIVATIVE; BESTATIN; BUTENOLIDE; CAPTOPRIL; CISAPRIDE; CYTOSTATIC AGENT; DEFOROLIMUS; DYSIDIOLIDE; E 7389; EMETINE; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EPOTHILONE A; ERIBULIN; EVEROLIMUS; INDOLACTAM V; LINEZOLID; NATURAL PRODUCT; OXAZOLIDINEDIONE DERIVATIVE; PROTEIN INHIBITOR; PURVALANOL; PYRIMIDINE DERIVATIVE; RAPAMYCIN; ROSCOVITINE; TELEOCIDIN; TEMSIROLIMUS; UNINDEXED DRUG; VANCOMYCIN;

CLINICAL TRIAL; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; METHODOLOGY; NEOPLASM; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION;

BIOLOGICAL PRODUCTS; COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG DESIGN; MOLECULAR STRUCTURE; PHARMACEUTICAL PREPARATIONS; PROTEIN CONFORMATION; PROTEINS; SMALL MOLECULE LIBRARIES;

EID: 42949160050     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0704090     Document Type: Review

References (77)

1. Newman, D. J.; Cragg, G. M. Natural products as sources of new drugs over the last 25 years. J. Nat. Prod. 2007, 70, 461-477.
2. Slee, A. M.; Wuonola, M. A.; McRipley, R. J.; Zajac, I.; Bartholomew, P. T.; Gregory, W. A.; Forbes, M. Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721. Antimicrob. Agents Chemother. 1987, 31, 1791-1797.
3. Daly, J. S.; Eliopoulos, G. M.; Reiszner, E.; Moellering Jr, R. C. Activity and mechanism of action of DuP 105 and DuP721. New oxazolidinone compounds. J. Antimicrob. Chemother. 1988, 21, 721-730.
4. Eustice, D. C.; Feldman, P. A.; Zajac, I.; Slee, A. M. Mechanism of action of DuP 721: inhibition of an early event during initiation of protein synthesis. Antimicrob. Agents Chemother. 1988, 32, 1218-1222.
5. Gregory, W. A.; Britelli, D. R.; Wang, C.-L. J.; Wuonola, M. A.; McRipley, R. J.; Eustice, D. C.; Eberley, V. S.; Bartholomew, P. T.; Slee, A. M.; Forbes, M. Antibacterials. Synthesis and structure-activity studies of 3-aryl-2-oxooxazolidines. J. Med. Chem. 1989, 32, 1673-1681.
6. Eustice, D. C.; Britelli, D. R.; Feldman, P. A.; Borkowski, J. J.; Slee, A. M. An automated pulse labelling method for structure-activity relationship studies with antibacterial oxazolidinones. Drugs Exp. Clin. Res. 1990, 16, 149-155.
7. Rouhi, A. M. Rediscovering natural products. Chem. Eng. News 2003, 81, 77-91.
8. Henkel, T.; Brunne, R. M.; Muller, H.; Reichel, F. Statistical investigation into the structural complementarity of natural products and synthetic compounds. Angew. Chem., Int. Ed. 1999, 38, 643-647.
9. Burke, M. D.; Lalic, G. Teaching target-oriented and diversity-oriented organic synthesis at Harvard University. Chem. Biol. 2002, 9, 535-541.
10. Schreiber, S. L. Target-oriented and diversity-oriented organic synthesis in drug discovery. Science 2000, 287, 1964-1969.
11. Nicolaou, K. C.; Pfefferkorn, J. A.; Roecker, A. J.; Cao, G. Q.; Barluenga, S.; Mitchell, H. J. Natural product-like combinatorial libraries based on privileged structures. 1. General principles and solid phase synthesis of benzopyrans. J. Am. Chem. Soc. 2000, 122, 9939-9953.
12. Nicolaou, K. C.; Pfefferkorn, J. A.; Mitchell, H. J.; Roecker, A. J.; Barluenga, S.; Cao, G. Q.; Affleck, R. L.; Lillig, J. E. Natural-product like combinatorial libraries based on privileged structures. 2. Construction of a 10,000-membered benzopyran library by directed split-and-pool chemistry using nanokans and optical encoding. J. Am. Chem. Soc. 2000, 122, 9954-9967.
13. Nicolaou, K. C.; Pfefferkorn, J. A.; Barluenga, S.; Mitchell, H. J.; Roecker, A. J.; Cao, G. Q. Natural product-like combinatorial libraries based on privileged structures. 3. The "libraries from libraries" principle for diversity enhancement of benzopyran libraries. J. Am. Chem. Soc. 2000, 122, 9968-9976.
14. Evans, B. E.; Rittle, K. E.; Bock, M. G.; DiPardo, R. M.; Freidinger, R. M.; Whitter, W. L.; Lundell, G. F.; Veber, D. F.; Anderson, P. S.; Chang, R. S. L.; Lotti, V. J.; Cerino, D. J.; Chen, T.; Kling, P. J.; Kunkel, K. A.; Springer, J. P.; Hirshfield, J. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. J. Med. Chem. 1988, 31, 2235-2246.
15. Mason, J. S.; Morize, I.; Menard, P. R.; Cheney, D. L.; Hulme, C.; Labaudiniere, R. F. New 4-point pharmacophore method for molecular similarity and diversity applications: overview of the method and applications, including a novel approach to the design of combinatorial libraries containing privileged substructures. J. Med. Chem. 1999, 42, 3251-3264.
16. Wiley, R. A.; Rich, D. H. Peptidomimetics derived from natural products. Med. Res. Rev. 1993, 13, 327-384.
17. Nicolaou, K. C.; Pfefferkorn, J. A.; Schuler, F.; Roecker, A. J.; Cao, G. Q.; Casida, J. E. Combinatorial synthesis of novel and potent inhibitors of NADH: ubiquinone oxidoreductase. Chem. Biol. 2000, 7, 979-992.
18. Nicolaou, K. C.; Roecker, A. J.; Barluenga, S.; Pfefferkorn, J. A.; Cao, G. Q. Discovery of novel antibacterial agents active against methicillin-resistant Staphylococcus aureus from combinatorial benzopyran libraries. ChemBioChem 2001, 2, 460-465.
19. Nicolaou, K. C.; Evans, R. M.; Roecker, A. J.; Hughes, R.; Downes, M.; Pfefferkorn, J. A. Discovery and optimization of non-steroidal FXR agonists from natural product-like libraries. Org. Biomol. Chem. 2003, 1, 908-920.
20. Downes, M.; Verdecia, M. A.; Roecker, A. J.; Hughes, R.; Hogenesch, J.; Kast-Woelbern, H. R.; Bowman, M. E.; Ferrer, J. L.; Anisfeld, A. M.; Edwards, P. A.; Rosenfeld, J. M.; Alvarez, J. G. A.; Noel, J. P.; Nicolaou, K. C.; Evans, R. M. A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol. Cell 2003, 11, 1079-1092.
21. Tan, C.; de Noronha, R. G.; Roecker, A. J.; Pyrzynska, B.; Khwaja, F.; Zhang, Z.; Zhang, H.; Teng, Q.; Nicholson, A. C.; Giannakakou, P.; Zhou, W.; Olson, J. J.; Pereira, M. M.; Nicolaou, K. C.; Van Meir, E. G. Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res. 2005, 65, 605-612.
22. Nicolaou, K. C.; Pfefferkorn, J. A. Solid phase synthesis of complex natural products and libraries thereof. Biopolymers 2001, 60, 171-193.
23. Meijer, L. Cyclin dependent kinase inhibitors as potential anticancer, antineurodegenerative, antiviral and antiparasitic Agents. Drug Resist. Updates 2000, 3, 83-88.
24. Meijer, L.; Raymond, E. Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials. Acc. Chem. Res. 2003, 36, 417-425.
25. Parker, C. W.; B, E.; Letham, D. S. Inhibitors of two enzymes which metabolize cytokinins. Phytochemistry 1986, 25, 303-310.
26. Chang, Y. T.; Gray, N. S.; Rosania, G. R.; Sutherlin, D. P.; Kwon, S.; Norman, T. C.; Sarohia, R.; Leost, M.; Meijer, L.; Schultz, P. G. Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors. Chem. Biol. 1999, 6, 361-375.
27. Benson, C.; White, J.; Bono, J. D.; O'donnell, A.; Raynaud, F.; Cruickshank, C.; McGrath, H.; Walton, M.; Workman, P.; Kaye, S.; Cassidy, J.; Gianella-Borradori, A.; Judson, I.; Twelves, C. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-roscovitine), administered twice daily for 7 days every 21 days. Br. J. Cancer 2007, 96, 29-37.
28. Chang, Y. T.; Choi, S.; Bae, Y. S.; Burdett, M.; Moon, H. S.; Lee, J. W.; Gray, N. S.; Schultz, P. G.; Meijer, L.; Chung, S.-K.; Choi, K. Y.; Suh, P.-G.; Yu, S. H. Purine-based inhibitors of inositol-1,4,5-trisphosphate-3-kinase. ChemBioChem 2002, 3, 897-901.
29. Armstrong, J. L.; Portley, A. R.; Chang, Y. T.; Nierengarten, D. M.; Cook, B. N.; Bowman, K. G.; Bishop, A.; Gray, N. S.; Shokat, K. M.; Schultz, P. G.; Bertozzi, C. R. Discovery of carbohydrate sulfotransferase inhibitors from a kinase-directed library. Angew. Chem., Int. Ed. 2000, 39, 1303-1306.
30. Chapman, E.; Ding, S.; Schulte, P. G.; Wong, C. H. A potent and highly selective sulfotransferase inhibitor. J. Am. Chem. Soc. 2002, 124, 14524-14525.
31. Rath, V. L.; Verdugo, D.; Hemmerich, S. Sulfotransferase structural biology and inhibitor discovery. Drug Discovery Today 2004, 9, 1003-1011.
32. Meseguer, B.; Alonso-Diaz, D.; Griebenow, N.; Herget, T.; Waldmann, H. Natural product synthesis on polymeric supports - synthesis and biological evaluation of an indolactam library. Angew. Chem., Int. Ed. 1999, 38, 2902-2906.
33. Meseguer, B.; Alonso-Diaz, D.; Griebenow, N.; Herget, T.; Waldmann, H. Solid-phase synthesis and biological evaluation of a teleocidin library - discovery of a selective PKCδ down regulator. Chem. - Eur. J. 2000, 21, 3943-3957.
34. Breinbauer, R.; Manger, M.; Scheck, M.; Waldmann, H. Natural product guided compound library development. Curr. Med. Chem. 2002, 9, 2129-2145.
35. Yu, M. J.; Kishi, Y.; Littlefield, B. A. Discovery of E7389, a Fully Synthetic Macrocyclic Ketone Analog of Halichondrin B. In Anticancer Agents from Natural Products; Cragg, G. M., Kingston, D. G. I., Newman, D. J., Eds.; Taylor and Francis: Boca Raton, FL, 2005; pp 241-265.
36. Tsang, C. K.; Qi, H.; Liu, L. F.; Zheng, X. F. S. Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discovery Today 2007, 12, 112-124.
37. Koehn, F. E. Therapeutic potential of natural product signal transduction agents. Curr. Opin. Biotechnol. 2006, 17, 631-637.
38. Perutz, M. F. Stereochemistry of cooperative effects in haemoglobin. Nature 1970, 228, 726-734.
39. Ebert, B.; Andersen, S.; Krogsgaard-Larsen, P. Ketobemidone, methadone and pethidine are non-competitive N-methyl-D-aspartate (NMDA) antagonists in the rat cortex and spinal cord. Neurosci. Lett. 1995, 187, 165-168.
40. Callahan, R. J.; Au, J. D.; Paul, M.; Liu, C.; Yost, C. S. Functional inhibition by methadone of N-methyl-D-aspartate receptors expressed in Xenopus oocytes: stereospecific and subunit effects. Anesth. Analg. 2004, 98, 653-659.
41. Krueger, K. E. Peripheral-type benzodiazepine receptors: a second site of action for benzodiazepines. Neuropsychopharmacology 1991, 4, 237-244.
42. Finlayson, K.; Witchel, H. J.; McCulloch, J.; Sharkey, J. Acquired QT interval prolongation and HERG: Implications for drug discovery and development. Eur. J. Pharmacol. 2004, 500, 129-142.
43. Brohm, D.; Metzger, S.; Bhargava, A.; Muller, O.; Lieb, F.; Waldmann, H. Natural products are biologically validated starting points in structural space for compound library development: Solid-phase synthesis of dysidiolide-derived phosphatase inhibitors. Angew. Chem., Int. Ed. 2002, 41, 307-311.
44. Kobayashi, J.; Madono, T.; Shigemori, H. Nakijiquinones C and D, new sesquiterpenoid quinones with an hydroxy amino acid residue from a marine sponge inhibiting c-Erb2 kinase. Tetrahedron 1995, 51, 10867-10974.
45. Stahl, P.; Kissau, L.; Mazitschek, R.; Giannis, A.; Waldmann, H. Natural product derived receptor tyrosine kinase inhibitors: identification of IGF1R, Tie-2 and VEGFR-3 inhibitors. Angew. Chem., Int. Ed. 2002, 41, 1174-1178.
46. Breinbauer, R.; Vetters, I.; Waldmann, H. From protein domain to drug candidates. Natural products as guiding principles in the design and synthesis of compound libraries. Angew. Chem., Int. Ed. 2002, 41, 2878-2890.
47. Zhou, B. N.; Johnson, R. K.; Mattern, M. R.; Fisher, P. W.; Kingston, D. G. I. The first naturally occurring Tie2 kinase inhibitor. Org. Lett. 2002, 3, 4047-4049.
48. Arnold, L. D.; Calderwood, D. J.; Dixon, R. W.; Johnston, D. N.; Kamens, J. S.; Munschauer, R.; Rafferty, P.; Ratnofsky, S. E. Pyrrolo[2,3-d] pyrimidines containing an extended 5-substituent as potent and selective inhibitors of Lck-1. Bioorg. Med. Chem. Lett. 2000, 10, 2167-2170.
49. Burchat, A. F.; Calderwood, D. J.; Hirst, G. C.; Holman, N. J.; Johnston, D. N.; Munschauer, R.; Rafferty, P.; Tometzki, G. B. Pyrrolo[2,3-d] pyrimidines containing an extended 5-substituent as potent and selective inhibitors of Lck-II. Bioorg. Med. Chem. Lett. 2000, 10, 2171-2174.
50. Calderwood, D. J.; Johnston, D. N.; Munschauer, R.; Rafferty, P. Pyrrolo[2,3-d]pyrimidines containing diverse N-7 substituents as potent inhibitors of Ick. Bioorg. Med. Chem. Lett. 2002, 12, 1683-1686.
51. Burchat, A. F.; Calderwood, D. J.; Friedmann, M. M.; Hirst, G. C.; Li, B.; Rafferty, P.; Ritter, K.; Skinner, B. S. Pyrazolo[3,4-d]pyrimidines containing an extended 3-substituent as potent inhibitors of lck - a selective insight. Bioorg. Med. Chem. Lett. 2002, 12, 1687-1690.
52. Koonin, E. V.; Wolf, Y. I.; Karev, G. P. The structure of the protein universe and genome evolution. Nature 2002, 420, 218-223.
53. 4 hydrolase. Bioorg. Med. Chem. 1995, 3, 969-995.
54. Zhang, M.-Q. A new target for antiinflammatory intervention. Curr. Med. Chem. 1997, 4, 67-78.
55. Brohm, D.; Philippe, N.; Metzger, B., A.; Muller, O.; Lieb, F.; Waldmann, H. Solid-phase synthesis of dysidiolide-derived protein phosphatase inhibitors. J. Am. Chem. Soc. 2002, 124, 13171-13178.
56. Kissau, L.; Stahl, P.; Mazitschek, R.; Giannis, A.; Waldmann, H. Development of natural product-derived receptor tyrosine kinase inhibitors based on conservation of protein domain fold. J. Med. Chem. 2003, 46, 2917-2931.
57. Koch, M. A.; Wittenberg, L.-O.; Basu, S.; Jeyaraj, D. A.; Gourzoulidou, E.; Reinecke, K.; Odermatt, A.; Waldmann, H. Compound library development guided by protein structure similarity clustering and natural product Structure. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 16721-16726.
58. Bialy, L.; Waldmann, H. Inhibitors of protein tyrosine phosphatases: next generation drugs. Angew. Chem., Int. Ed. 2005, 44, 3814-3839.
59. Koch, M. A.; Waldmann, H. Protein structure similarity clustering and natural product structure as guiding principles in drug discovery. Drug Discovery Today 2005, 10, 471-483.
60. Byrd, J. C.; Park, J. H. Y.; Schaffer, B. S.; Garmroudi, F.; MacDonald, R. G. Dimerization of the insulin-like growth factor II/mannose 6-phosphate receptor. J. Biol. Chem. 2000, 275, 18647-18656.
61. Byrd, J. C.; MacDonald, R. G. Mechanisms for high affinity mannose 6-phosphate ligand binding to the insuln-like growth factor II/mannose 6-phosphate receptor. J. Biol. Chem. 2000, 275, 18638-18646.
62. Siegenthaler, G.; Hotz, R.; Chatellard-Gruaz, D.; Jaconi, S.; Saurat, J.-H. Characterization and expression of a novel human fatty acid-binding protein: the epidermal type (E-FABP). Biochem. Biophys. Res. Commun. 1993, 190, 482-487.
63. Charette, B. D.; MacDonald, R. G.; Wetzel, S.; Berkowitz, D. B.; Waldmann, H. Protein structure similarity clustering: dynamic treatment of PDB structures facilitates clustering. Angew. Chem., Int. Ed. 2006, 45, 7766-7770.
64. Koch, M. A.; Schuffenhauer, A.; Scheck, M.; Wetzel, S.; Casaulta, M.; Odermatt, A.; Ertl, P.; Waldmann, H. Charting biologically relevant chemical space: a structural classification of natural products (SCONP). Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 17272-17277.
65. Schuffenhauer, A.; Ertl, P.; Roggo, S.; Wetzel, S.; Koch, M. A.; Waldmann, H. The scaffold tree. Visualization of the scaffold universe by hierarchical scaffold classification. J. Chem. Inf. Model. 2007, 47, 47-58.
66. Arve, L.; Voigt, T.; Waldmann, H. Charting biological and chemical space: PSSC and SCONP as guiding principles for the development of compound collections based on natural product scaffolds. QSAR Comb. Sci. 2006, 25, 449-456.
67. Noren-Muller, A.; Reis-Correa, I., Jr.; Prinz, H.; Rosenbaum, C.; Saxena, K.; Schwalbe, H. J.; Vestweber, D.; Cagna, G.; Schunk, S.; Schwarz, O.; Schiewe, H.; Waldmann, H. Discovery of protein phosphatase inhibitor classes by biology-oriented synthesis. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 1060-10611.
68. McArdle, B. M.; Campitelli, M. R.; Quinn, R. J. A common protein fold topology shared by flavanoid biosynthetic enzymes and therapeutic targets. J. Nat. Prod. 2006, 69, 14-17.
69. Keiser, M. J.; Roth, B. L.; Armbruster, B. N.; Ernsberger, P.; Irwin, J. J.; Shoichet, B. K. Relating protein pharmacology by ligand chemistry. Nat. Biotechnol. 2007, 25, 197-206.
70. Beiner, M. Proteins: Is the folding process dynamically encoded? Soft Matter 2007, 3, 391-393.
71. Wales, D. J.; Bogdan, T. V. Potential energy and free energy landscapes. J. Phys. Chem. B 2006, 110, 20765-20776.
72. Costantino, L.; Barlocco, D. Privileged structures as leads in medicinal chemistry. Curr. Med. Chem. 2006, 13, 65-85.
73. Milroy, L.-G.; Zinzalla, G.; Prencipe, G.; Michel, P.; Ley, S. P.; Gunaratnam, M.; Beltran, M.; Neidle, S. Chemical variation of natural-product-like scaffolds: design, synthesis, and biological activity of fused bicyclic acetal derivatives. Angew. Chem., Int. Ed. 2007, 46, 2493-2496.
74. Yin, H.; Hamilton, A. D. Strategies for targeting protein-protein interactions with synthetic agents. Angew. Chem., Int. Ed. 2005, 44, 4130-4163.
75. Newman, D. J. Natural products as leads to potential drugs: an old process or the new hope for drug discovery. Abst. Pap. - Am. Chem. Soc. 2006, 467, ORGN.
76. Haustedt, L. O.; Mang, C.; Siems, K.; Schiewe, H. Rational approaches to natural-product-based drug design. Curr. Opin. Drug Discovery Dev. 2006, 9, 445-462.
77. Baran, P. S.; Maimone, T. J.; Richter, J. M. Total synthesis of marine natural products without using protecting groups. Nature 2007, 446, 404-408.